|本期目录/Table of Contents|

[1]刘斌,谢波,黄彭,等.PD-1抑制剂相关性肺炎并肺孢子菌肺炎一例[J].中华肺部疾病杂志,2022,(06):923-925.[doi:10.3877/cma.j.issn.1674-6902.2022.06.044]
点击复制

PD-1抑制剂相关性肺炎并肺孢子菌肺炎一例(PDF)

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2022年06期
页码:
923-925
栏目:
病例报告
出版日期:
2022-12-20

文章信息/Info

Title:
-
作者:
刘斌1; 谢波2; 黄彭1; 刘双柏1; 梁彦超1; 陈芳玮1; 徐藤娟1
412007 株洲,湖南省株洲市中心医院?中南大学湘雅医学院附属株洲医院呼吸与危重症医学科一病区1、医务部质控办2
Author(s):
-
关键词:
PD-1抑制剂;  肺孢子菌;  肺炎
Keywords:
-
分类号:
R563
DOI:
10.3877/cma.j.issn.1674-6902.2022.06.044
摘要:
-
Abstract:
-

参考文献/References:

1 Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies[J]. Ann Oncol, 2015, 26(12): 2375-2391.
2 Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy[J]. J Clin Oncol, 2017, 35(7): 709-717.
3 Widmann G, Nguyen VA, Plaickner J, et al. Imaging features of toxicities by immune checkpoint inhibitors in cancer therapy[J]. Curr Radiol Rep, 2016, 5(11): 59.
4 李 珊, 孙宇新, 黄 慧, 等. 免疫检查点抑制剂相关性间质性肺疾病的诊疗进展[J]. 中华结核和呼吸杂志, 2018, 41(12): 971-974.
5 Liu CJ, Lee TF, Ruan SY, et al. Clinical characteristics, treatment outcomes, and prognostic factors of Pneumocystis pneumonia in non-HIV-infected patients[J]. Infect Drug Resist, 2019, 12: 1457-1467.
6 Schmidt JJ, Lueck C, Ziesing S, et al. Clinical course, treatment and outcome of Pneumocystis pneumonia in immunocompromised adults: a retrospective analysis over 17 years[J]. Crit Care, 2018, 22(1): 307.
7 Fillatre P, Decaux O, Jouneau S, et al. Incidence of Pneumocystis jiroveci pneumonia among groups at risk in HIV-negative patients[J]. Am J Med, 2014, 127(12): 1211-1242.
8 Bienvenu AL, Traore K, Plekhanova I, et al. Pneumocystis pneumonia suspected cases in 604 non-HIV and HIV patients[J]. Int J Infect Dis, 2016, 46: 11-17.
9 Thomas CJ, Limper AH. Pneumocystis pneumonia[J]. N Engl J Med, 2004, 350(24): 2487-2498.
10 Cordonnier C, Cesaro S, Maschmeyer G, et al. Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients[J]. J Antimicrob Chemother, 2016, 71(9): 2379-2385.
11 Bienvenu AL, Traore K, Plekhanova I, et al. Pneumocystis pneumonia suspected cases in 604 non-HIV and HIV patients[J]. Int J Infect Dis, 2016, 46: 11-17.
12 Lee YT, Chuang ML. Pneumocystis jirovecii pneumonia in AIDS and non-AIDS immunocompromised patients-an update[J]. J Infect Dev Ctries, 2018, 12(10): 824-834.
13 张 健, 陈 平, 宋芹霞, 等. AIDS合并卡氏肺孢子菌肺炎的多排螺旋CT表现及鉴别诊断[J]. 中华全科医学, 2020, 18(11): 1901-1903.
14 王瑜琼, 黄琳娜, 詹庆元. 肺孢子菌肺炎诊断方法的研究进展[J]. 中华结核和呼吸杂志, 2020, 43(10): 878-880.
15 Botterel F, Cabaret O, Foulet F, et al. Clinical significance of quantifying Pneumocystis jirovecii DNA by using real-time PCR in bronchoalveolar lavage fluid from immunocompromised patients[J]. J Clin Microbiol, 2012, 50(2): 227-231.
16 Cooley L, Dendle C, Wolf J, et al. Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014[J]. Intern Med J, 2014, 44(12b): 1350-1363.
17 卓惠长, 林建东, 尤彦菁. 基于宏基因组学的二代测序技术在肾移植术后重症肺炎诊治中的应用[J]. 中华器官移植杂志, 2019, 40(6): 361-364.
18 贾建超, 贾建敏, 刘 姿, 等. 宏基因组学二代测序技术对重症肺炎真菌感染诊断价值[J]. 中华实用诊断与治疗杂志, 2020, 34(10): 1023-1025.
19 于 婧, 肖冉冉, 顾 莹, 等. 非HIV感染免疫抑制肺孢子菌肺炎临床特点分析[J]. 疑难病杂志, 2020, 19(10): 1013-1015.
20 李侗曾, 梁连春. 肺孢子菌肺炎的治疗进展[J]. 国际呼吸杂志, 2020, 40(2): 151-152.
21 Pareja JG, Garland R, Koziel H. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia[J]. Chest, 1998, 113(5): 1215-1224.
22 Lemiale V, Debrumetz A, Delannoy A, et al. Adjunctive steroid in HIV-negative patients with severe Pneumocystis pneumonia[J]. Respir Res, 2013, 14: 87.

备注/Memo

备注/Memo:
通信作者: 谢 波, Email: potter0712@126.com
更新日期/Last Update: 2022-12-20